ASH 2022 | The impact of daratumumab on stem cell mobilization in patients with multiple myeloma
Ravi Vij, MD, MBA, Washington University Medical School, St. Louis, MO, comments on the results of a study that evaluated the stem cell yield of plerixafor and G-CSF-treated patients with multiple myeloma who had been exposed to daratumumab. Overall, it was found that daratumumab exposure leads to reduced stem cell mobilization. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Honoraria, Research Funding; Oncopeptides: Honoraria; Harpoon: Consultancy; Adaptive: Honoraria; Sanofi: Honoraria, Research Funding; GSK: Honoraria; Pfizer: Honoraria; BMS: Honoraria, Research Funding; Legend: Honoraria; Biegene: Honoraria; Janssen: Honoraria; CareDx: Honoraria.
